Lorbrena® (lorlatinib) – Expanded indication
March 3, 2021 - Pfizer announced the FDA approval of Lorbrena (lorlatinib), for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Top